Shionogi & Co., Ltd., established in 1878 and headquartered in Osaka, Japan, is a research-driven pharmaceutical company known for its focus on infectious diseases, pain management, cardiovascular-metabolic conditions, and central nervous system disorders. Over its more than a century-long history, Shionogi has built a diverse portfolio through both in-house development and strategic collaborations, bringing a range of innovative therapies to market, particularly in the field of anti-infectives and antiviral treatments.
In the anti-infectives segment, Shionogi is widely recognized for its efforts to combat antimicrobial resistance, with key products such as the carbapenem antibiotic doripenem. The company has also advanced antiviral agents for influenza and other viral infections, often in partnership with global industry leaders to support broader public health initiatives. Beyond infectious diseases, Shionogi’s R&D pipeline includes novel analgesics for acute and chronic pain and investigational programs addressing metabolic disorders and neurological conditions.
Shionogi extends its operations across Japan, North America, Europe and the Asia-Pacific region through subsidiaries, licensing agreements and co-development partnerships. This international footprint is reinforced by alliances with leading pharmaceutical firms, enabling the company to accelerate development timelines and expand global distribution networks. Guided by a commitment to scientific excellence and patient-centric innovation, Shionogi continues to invest heavily in research, seeking to address unmet medical needs and improve health outcomes worldwide.
AI Generated. May Contain Errors.
